financetom
Business
financetom
/
Business
/
Landsea Homes Reports Closing of Secondary Stock Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Landsea Homes Reports Closing of Secondary Stock Offering
Mar 8, 2024 2:18 PM

04:52 PM EST, 03/08/2024 (MT Newswires) -- Landsea Homes ( LSEA ) said late Friday that Landsea Holdings closed its offering of about 2.43 million shares, including over-allotment option, at $11.60 per share.

Following the close of the offering, Landsea Holdings no longer owns a majority of its shares and Landsea Homes ( LSEA ) no longer qualifies as a "controlled company" according to Nasdaq listing standards.

The company said it is currently in compliance with and intends to comply with the transition period requirements applicable following the loss of such status under the Nasdaq listing standards.

Price: 13.27, Change: -0.15, Percent Change: -1.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jana urges Lamb Weston board to fix company or put itself up for sale
Jana urges Lamb Weston board to fix company or put itself up for sale
Dec 16, 2024
NEW YORK, Dec 16 (Reuters) - Activist investor Jana Partners urged Lamb Weston ( LW ) on Monday to replace board members and top executives to improve its performance or else put itself up for sale. Lamb Weston's ( LW ) Board and management have wasted the chance to sustain and grow shareholder value in a high-quality business, the hedge...
Corcept Therapeutics' Phase 3 Study of Relacorilant Shows Improvements in Patients With Hypercortisolism
Corcept Therapeutics' Phase 3 Study of Relacorilant Shows Improvements in Patients With Hypercortisolism
Dec 16, 2024
09:29 AM EST, 12/16/2024 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Monday that results from its phase 3 study of relacorilant to treat patients suffering from endogenous hypercortisolism showed clinically meaningful and durable cardiometabolic improvements. Hypercortisolism, or Cushing's syndrome, occurs when the body produces too much cortisol, which can cause high blood pressure leading to increased cardiovascular risk...
Argentina's YPF forms partnership for Vaca Muerta Sur oil project
Argentina's YPF forms partnership for Vaca Muerta Sur oil project
Dec 16, 2024
BUENOS AIRES, Dec 16 (Reuters) - Argentina's state-run oil company YPF formed a partnership called VMOS S.A. with oil companies Vista Energy Argentina, Pampa Energia and Pan American Sur to export oil from the Vaca Muerta shale formation, the company announced on Monday. ...
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
Dec 16, 2024
Foghorn Therapeutics Inc. ( FHTX ) shares are trading lower by 8.49% to $4.85 during Monday’s session after the company announced it will discontinue independent development of its FHD-286 program in combination with decitabine for relapsed/refractory acute myeloid leukemia (AML) due to insufficient response rates in a Phase 1 trial. What To Know: While Foghorn says clinical responses were observed,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved